China Pharma Holdings, Inc.
CPHI
$0.82
-$0.02-2.38%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -10.97% | -7.08% | -8.49% | -26.91% | -29.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.97% | -7.08% | -8.49% | -26.91% | -29.64% |
| Cost of Revenue | -34.83% | -39.58% | -34.36% | -39.65% | -32.63% |
| Gross Profit | 150.95% | 115.81% | 93.35% | 76.71% | 44.16% |
| SG&A Expenses | 69.97% | 53.27% | 21.86% | 20.43% | 20.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.45% | -14.77% | -20.69% | -29.50% | -24.07% |
| Operating Income | -23.58% | 22.23% | 32.72% | 32.63% | 15.80% |
| Income Before Tax | -22.39% | 22.36% | 32.70% | 32.76% | 16.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.39% | 22.36% | 32.70% | 32.76% | 16.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.39% | 22.36% | 32.70% | 32.76% | 16.97% |
| EBIT | -23.58% | 22.23% | 32.72% | 32.63% | 15.80% |
| EBITDA | 17.50% | 41.78% | 19.64% | 4.79% | -28.99% |
| EPS Basic | 72.82% | 75.86% | 72.95% | 72.05% | 74.67% |
| Normalized Basic EPS | 72.83% | 75.86% | 72.95% | 72.04% | 74.67% |
| EPS Diluted | 72.82% | 75.86% | 72.95% | 72.05% | 74.67% |
| Normalized Diluted EPS | 72.83% | 75.86% | 72.95% | 72.04% | 74.67% |
| Average Basic Shares Outstanding | 629.22% | 342.79% | 145.19% | 134.44% | 167.30% |
| Average Diluted Shares Outstanding | 629.22% | 342.79% | 145.19% | 134.44% | 167.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |